Sandoz Reports the US FDA’s Approval of Wyost and Jubbonti (Biosimilar, Denosumab)
Shots:
- Sandoz has received the US FDA’s approval for Wyost & Jubbonti (denosumab-bbdz), biosimilars of Xgeva & Prolia (denosumab), based on the clinical studies demonstrating their similarity with the reference drugs
- The company’s Jubbonti Risk Evaluation & Mitigation Strategy (REMS) program has also been approved to educate HCPs & patients about the severe hypocalcemia risk associated with Jubbonti in advanced CKD, incl. dialysis-dependent patients
- Wyost is indicated for preventing SREs in MM patients & solid tumor bone metastases, giant cell bone tumor & refractory hypercalcemia while Jubbonti is approved for osteoporosis in postmenopausal women & to increase bone mass associated with certain conditions
Ref: Sandoz | Image: Sandoz
Related News:- Coherus BioSciences to Divest its Ophthalmology Franchise to Sandoz for $170M Up Front
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
